News Releases

First centrally registered vaccine in the European Union against the currently circulating avian influenza virus strains of clade 2.3.4.4b RAHWAY, N.J., May 24, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission has granted the marketing authorization for the INNOVAX®-ND-H5 vaccine for […]

Read more

If approved by the European Commission, the vaccine will become an available tool for governments to consider as part of a holistic strategy to combat the spread of highly pathogenic avian influenza (HPAI) which may include additional vaccinations plus enhanced biosecurity and surveillance Potentially the first centrally registered vaccine in the European Union against the […]

Read more